Health Products

LEO 22811-S22 Proof of Concept Study (Phase II)

· Published by Health Canada · Official notice

Details

Alert type: Drug Recall
Category: Drugs
Issue: Product Safety, Quality
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type III
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberCommon nameCompaniesDosage formDIN, NPN, DIN-HIMStrength
Bulk Batch No. 09 301 71 01LEO 22811-S22 Proof of Concept Study (Phase II)
Recalling Firm
LEO Pharma 123 Commerce Valley Drive East, Suite 400, Thornhill, Ontario L3T 7W8
Marketing Authorization Holder
N/A
Recalling Firm
LEO Pharma
Oral SolutionN/A -Clinical Trial (IMP)Placebo of LEO 22811

Introduction

Recalled products
  1. LEO 22811-S22 Proof of Concept Study (Phase II)

Reason

Broken bottles and loose caps have been identified. A significant part of the bottles with loose caps are leaking.

Depth of distribution

The IMP has been distributed to six clinical sites in France, four clinical sites in Canada as well as one central depot in both France and Canada.
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime